Six-year antibody response after one dose of the 9‑valent HPV vaccine in students
Official title: Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
Run by Canadian Immunization Research Network · NCT07156084 · Data updated 2026-11-12
We will test whether one dose of the 9‑valent (9vHPV) vaccine given to 9–11‑year‑old students in 2019–2020 still produces antibodies six years later.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 15 Years to 17 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Canadian Immunization Research Network Research network |
| Locations | 1 site (Québec, Quebec) |
| Status | Recruiting |
| Started | September 23, 2025 |
| Main results expected | February 2026 |
| Study ends | February 2026 |
| Registry record updated | September 29, 2025 |
| Trial ID | NCT07156084 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Immunocompetent youth who received exactly one 9vHPV dose at ages 9–11 during the 2019–2020 Grade 4 school program and can consent are ideal candidates.
✕Probably not a fit
Individuals who received additional HPV vaccine doses, are immunosuppressed, or were vaccinated outside the 2019–2020 Grade 4 program are unlikely to benefit from or be eligible for this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers at CHU de Québec‑Université Laval will recruit about 300 youth (approximately 150 girls and 150 boys) who received a single 9vHPV dose in Grade 4 during 2019–2020. Participants will complete a brief questionnaire and provide a blood sample to measure HPV antibody levels roughly six years after vaccination. Eligible participants must have received exactly one 9vHPV dose at ages 9–11 and be immunocompetent; anyone who received additional HPV doses or is immunosuppressed will be excluded. The results will describe persistence of antibody responses at an age when many begin sexual activity and help inform local and national vaccination policy.
Why it matters
Potential benefit: If antibody levels remain detectable six years after one dose, this could support that a single 9vHPV dose provides lasting immune protection and simplify vaccination schedules.
How similar studies have gone: Observational studies and policy reviews have shown encouraging immune responses and real-world protection after single-dose HPV schedules, prompting WHO and Canadian recommendations, but long-term data—especially in boys—remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have received a single dose of 9vHPV vaccine at ages 9-11 during the school year 2019-2020; * Not have received any other HPV vaccine doses; * Be able to consent to the study. Exclusion Criteria: * Immunosuppressed (at recruitment or when immunized).
Where it's running
-
Centre de recherche du CHU de Québec-Université Laval
Québec, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Chantal Sauvageau, MD — INSPQ and Laval University
- Study coordinator: Chantal Sauvageau, MD
- Email: chantal.sauvageau@inspq.qc.ca
- Phone: 418650-5115
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Digital tools to boost HPV vaccination intentions among Nigerian caregivers
This study tests whether different online content can help Nigerian parents of unvaccinated girls ages 9-14 decide to vaccinate their daughters against HPV.
-
HPV Immunization in Ghana to See if Vaccine Works in Babies and Teens
This study tests whether a bivalent HPV vaccine is safe and can provoke an immune response in healthy infants and young children, and compares it to responses seen in unmarried young women aged 15–20 in Ghana.
-
Increasing HPV vaccine uptake among young patients
This study is testing a new approach to help more young patients aged 10-12 get the HPV vaccine at clinics in California.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.